https://orcid.org/0000-0001-5340-1818
Key Points
Nivolumab-based triplet therapy is an effective salvage strategy to restore sensitivity to CAR-T cell therapy in selected myeloma patients
Response to PD-1 inhibition after CAR-T is dictated by the fitness state of non-CAR T cells
Subjects:
Immunobiology and Immunotherapy
Efficacy and durability remain central shortcomings of T-cell based therapies in multiple myeloma (MM). Here, we employ blood-based transcriptional T-cell profiling to define impaired T-cell fitness as putative biomarker associated with sensitivity to PD1 inhibition in CAR-T refractory MM patients.
Subjects:
Immunobiology and Immunotherapy
This content is only available as a PDF.
Copyright © 2025 American Society of Hematology
2025
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
